Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in... see more

TSXV:VPT - Post Discussion

VentriPoint Diagnostics Ltd > China. That's official now
View:
Post by ScienceFirst on Feb 16, 2021 8:15am

China. That's official now

Ventripoint Advances Sales, Marketing, and Distribution Partnership in the Largest Market in World for Heart Disease: China

Here is some background:
 
1. Ventripoint and Yutian have been working together for a number of years to address the Chinese market.
2. The bulk of the effort has been done by Yutian, who have designed new machines they call QAS™, based upon Ventripoint’s technologies using mostly Chinese components.
3. They are approved in China for RV only and have built a manufacturing plant in Ma’anshan, as well as a development and research lab in Shanghai,
4. The NR reports they have 8 QAS machines operational in 8 key hospitals in 3 three different provinces totalling 168M people.
5.  China has the worst heart disease in the world due to the prevalence of risk factors (diabetes, obesity, excessive alcohol consumption, air pollution and smoking).
6.  China has 34,000 hospitals and the proportion of cardiac admissions (23%) is nearly twice the US rate at 14%.  
7.  Recent publications predict the number of people with heart disease will double in China by 2030 and this will add USD$7.8 trillion to the cost as their focus is on acute care.
8.   A second recent study observed they need better non-invasive screening tools for earlier detection and monitoring of heart disease.  This of course is where the QAS is aimed.
9. We continue to support Yutian with engineering and regulatory assistance so they can upgrade to 4 chamber analysis and our proprietary tracking technology and other upgrades already on the VMS+3.0.
10. They say they have built a pan-China distribution network and will start selling the QAS devices shortly. 
11. The unmet medical need in China is obvious and enormous, but I have learned that things in China take a lot longer than you expect.
 
As usual, I think you for your support and interest as we continue our mission to improve cardiac care worldwide and especially for children.
 
Comment by Sunvalley on Feb 16, 2021 8:37am
Does anyone know how the proposed Chinese sales will relate to the profit potential to VPT? In simple terms , how much money does VPT get for each unit sold in China. Thanks in advance.
Comment by snuff133 on Feb 16, 2021 8:55am
Dear Friend; Attached is the news release that will be published Feb 16 at 7:00 am EST.   Here is some background:   1. Ventripoint and Yutian have been working together for a number of years to address the Chinese market. 2. The bulk of the effort has been done by Yutian, who have designed new machines they call QAS ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities